26.55

0.23% 0.06

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$26.49

Aprire:

$26.42

Volume 24 ore:

1.59M

Relative Volume:

0.87

Capitalizzazione di mercato:

$4.38B

Reddito:

$1.51B

Utile/perdita netta:

$333.35M

Rapporto P/E:

13.62

EPS:

1.95

Flusso di cassa netto:

$315.22M

1 W Prestazione:

+1.61%

1M Prestazione:

-8.40%

6M Prestazione:

-15.79%

1 anno Prestazione:

-1.15%

Intervallo 1D:

$26.30

$26.68

Intervallo di 1 settimana:

$25.71

$28.67

Portata 52W:

$25.56

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1164)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

1,800

Cinguettio

@alkermes

Prossima data di guadagno

2024-10-24

Ultimi documenti SEC

ALKS's Discussions on Twitter

Confronta ALKS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	26.55	4.37B	1.51B	333.35M	315.22M	1.95
ZTS Zoetis Inc	147.38	64.91B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.16	43.33B	29.98B	958.27M	5.31B	0.2964
HLN Haleon Plc Adr	9.66	42.36B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.38	17.72B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	294.28	12.42B	2.99B	1.21B	1.13B	25.06

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-15	Iniziato	Goldman	Buy
2025-06-17	Aggiornamento	UBS	Neutral → Buy
2025-05-28	Iniziato	Needham	Buy
2025-03-13	Iniziato	RBC Capital Mkts	Sector Perform
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

07:28 AM

Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales - MSN

07:28 AM

06:09 AM

What catalysts could drive Alkermes plc stock higher in 2025Invest confidently with professional advice - jammulinksnews.com

06:09 AM

04:21 AM

Should I hold or sell Alkermes plc stock in 2025Get expert analysis on top stock picks - jammulinksnews.com

04:21 AM

03:59 AM

What is the dividend policy of Alkermes plc stockAccelerated profit realization - jammulinksnews.com

03:59 AM

03:25 AM

What are analysts’ price targets for Alkermes plc in the next 12 monthsAchieve rapid portfolio growth with expert guidance - jammulinksnews.com

03:25 AM

Aug 02, 2025

What are the technical indicators suggesting about Alkermes plcDiscover investment plans that deliver results - jammulinksnews.com

Aug 02, 2025

How strong is Alkermes plc company’s balance sheetUnlock powerful portfolio optimization tools - jammulinksnews.com

Aug 02, 2025

What markets is Alkermes plc expanding into Is ASLE stock a good long term investment optionBuild a portfolio that outperforms consistently - jammulinksnews.com

Aug 02, 2025

Alkermes Reports Q2 2025 Financial Results, Reiterates Expectations and Highlights Positive Clinical Study Results - AInvest

Aug 02, 2025

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire

Aug 02, 2025

Jul 31, 2025

Alkermes shares climb 5% following Q2 earnings and revenue beat - MSN

Jul 31, 2025

(07/31/25) ALKS: Positive Narcolepsy Drug Trial Puts this Biotech Name in F - moneyshow.com

Jul 31, 2025

Jul 30, 2025

Alkermes anticipates record proprietary product sales above $1B for 2025 as orexin pipeline advances - MSN

Jul 30, 2025

Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha

Jul 30, 2025

Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 30, 2025

Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat

Jul 30, 2025

Alkermes Beat Expectations With A Strong Second Quarter - Finimize

Jul 30, 2025

Schizophrenia Drugs Market Exclusive Report with Detailed - openPR.com

Jul 30, 2025